WHO ICTRP trial
Pharmacokinetics, Safety and Efficacy of Albuvirtide in HIV-1 Patients with End…
ChiCTR2200058014 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200058014 |
|---|---|
| Public title | Pharmacokinetics, Safety and Efficacy of Albuvirtide in HIV-1 Patients with End Stage Renal Disease Requiring Hemodialysis |
| Scientific title | Pharmacokinetics, Safety and Efficacy of Albuvirtide in HIV-1 Patients with End Stage Renal Disease Requiring Hemodialysis |
| Primary sponsor | Chongqing Public Health Medical Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Acquired Immune Deficiency Syndrome |
| Interventions | Experimental group:The first stage: Albvirtide+Dolutegravir+Lamifudine; The second stage: Albvirtide+Dolutegravir |
| Registration date | Mar 26, 2022 |
| Target size | Experimental group:10 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: